Shots:

• The study involves assessing of investigational vaccine mRNA-1273 against COVID-19 enrolling 45 patients with age of 18 to 55 years ~6wks. and the first patient has been dosed. Additionally- National Institute of Allergy and Infectious Diseases (NIAID) is funding the P-I trial
• The study will be evaluating two doses of the vaccine (IM- 25mcg- 100/250 mcg) in the upper arm ~ for 28 days apart due to its safety- and the ability to induce immune response. Till Mar 15- 2020 WHO has reported 153-517 cases of COVID-19 and 5-735 deaths worldwide with confirmed 2-800 cases and 58 deaths in the US
• mRNA-1273 is an investigational vaccine developed by NIAID scientists in collaboration with Moderna. Additionally- the adults in Seattle who are interested in joining the study needs to visit https://corona.kpwashingtonresearch.org

Click here to read full press release/ article | Ref: NIH | Image: Twitter